Clinical trials: Heartburn
Gastroesophageal Reflux Disease (GERD)
The EndoGastric Solutions TEMPO Trial
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal…
- Trial name
- TEMPO (NCT01647958)
- Testing
- EsophyX System with SerosaFuse fasteners, PPI
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- EndoGastric Solutions
Heartburn
Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn
This study will investigate the safety and efficacy of an antacid/Lansoprazole combination product for the relief of heartburn after consuming a heartburn-inducing meal.
- Trial name
- NCT01037452
- Testing
- Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Novartis
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
Functional Gastrointestinal Disorders
Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus
In this study researchers want to learn more about the effectiveness of Iberogast® in patients with irritable stomach and concomitant chronic or recurrent heartburn and backward flow of stomach liquid into the esophagus.
- Trial name
- NCT04059900
- Testing
- STW5 (Iberogast®, BAY98-7411)
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Bayer
Gastroesophageal Reflux Disease
Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.
To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment…
- Trial name
- NCT00786773
- Where
- 18 sites in Vietnam
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
GERD (Heartburn, Regurgitation, and Dyspepsia), Gastroesophageal Reflux (GERD)
A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients
This study involves a medical device in the form of syrup, not yet on the market and tested for the first time in humans, named "FIBROIN SYRUP".
- Trial name
- NCT07563790
- Testing
- Syrup made by hyaluronic acid
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Rose Pharma SA
Heartburn
A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes
This decentralized, randomized, double-blind, placebo-controlled, two-period crossover study will evaluate whether PepZinGI® (zinc-L-carnosine) reduces food-triggered heartburn compared with placebo.
- Trial name
- NCT07379645
- Testing
- PepZinGI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NutriScience Innovations, LLC
Frequent Heartburn
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
- Trial name
- NCT01286194
- Testing
- Rabeprazole sodium
- Where
- 33 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease, Erosive Esophagitis
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of…
- Trial name
- NCT01642615
- Testing
- Dexlansoprazole
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 63 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, GERD
Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn
- Trial name
- NCT00373334
- Testing
- nizatidine (axid)
- Where
- 26 sites in United States
- Volunteers
- 138 people
- Sponsor
- Braintree Laboratories
Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
- Trial name
- NCT00644735
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many patients when acidic stomach contents move into the esophagus from the stomach.
- Trial name
- NCT00389948
- Testing
- Lanzoprazole
- Where
- 28 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis
GERD
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with…
- Trial name
- NCT00242736
- Testing
- Esomeprazole
- Where
- 25 sites in United States
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
GERD Gastroesophageal Reflux Disease
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).
- Trial name
- CALIBER (NCT02505945)
- Testing
- Omeprazole, LINX Reflux Management System
- Where
- 21 sites in United States
- Volunteers
- 152 people
- Sponsor
- Torax Medical Incorporated
Gastroesophageal Reflux
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.
- Trial name
- NCT00820079
- Testing
- ADX10059
- Where
- 11 sites in Austria, Belgium and 2 more
- Volunteers
- 120 people
- Sponsor
- Addex Pharma S.A.